C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity - a disease responsible for approximately one in every 25 deaths worldwide1The test ...

The test enables earlier identification of patients with significant liver fibrosis, potentially improving outcomes through timely management and access to emerging therapies.

Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

Trump hosted top CEOs at the White House to announce over $8 trillion in U.S. investments. From AI chips to steel, here’s who ...

B-cell therapy for multiple sclerosis (MS) was first approved in 2017, after the anti-CD20 agent ocrelizumab (Ocrevus) ...

Patients with advanced solid tumors experienced significantly improved survival outcomes when receiving a tailored therapy ...

Patients with advanced solid tumors experienced significantly improved survival outcomes with tailored treatment guided by tissue plus liquid biopsies vs. individually, according to results presented ...

Arrivent Biopharma, a clinical-stage biopharmaceutical company, has recently appointed Dr. Merdad Parsey, M.D., Ph.D., to its ...